Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab plus atezolizumab with or without platinum-based chemotherapy in resectable locally advanced non-small cell lung cancer
2020-002853-11Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tiragolumab and atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Incidence and length of surgical delays, operative and post-operative complications, and surgical cancellations related to study treatment. Started Dec 2021; status: completed.
02
Drugs
tiragolumabatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-002853-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002853-11.